Product Images Clopidogrel Bisulfate

This is a description of a medication called Clopidogrel, which is available in unit dose tablets. The NDC codes for the medication are 0904-6204-61 and 0904-6294-61. The medication guide must be provided to the pharmacist upon dispensing. The dosage is 75 g per patient, and it should be stored at room temperature. The medication is available in a Uni-Dose package, which should be dispensed in the original container with the appropriate warning labels. The rest of the text is not legible.*

The text is describing a chart that shows the cumulative event rate for cardiovascular death, myocardial infarction, and stroke. The chart compares the event rate for patients who were given a placebo versus those who were given topidogrel bisuate and aspirin. The chart tracks 12 months of follow-up and other standard therapies were used as appropriate.*

The text presents a table with subgroup characteristics and hazard ratio for the CURE Study, which evaluates the effect of concomitant medications/interventions on patient baseline characteristics. The table shows information for subgroups based on age, gender, race, elevated cardiac enzyme, diabetes, previous myocardial infarction, and previous stroke. The hazard ratio with its 95% confidence interval is presented for each subgroup.*

The text provides a table and a title "Figure 3: Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study (continued)" from a study called CURE. It shows the hazard ratio and percentages for different patient baseline characteristics and their treatment with either clopidogrel or placebo. The table includes information on heparin/LMWH, aspirin dosage, GPIIb/IIIa Antag, beta-blocker, and ACE inhibitor. There is no additional information available in the text.*

This is a description of a figure showing the cumulative event rates for death in the COMMIT study. The study compared the effects of placebo and clopidogrel, and the figure displays the percentage of deaths in each group over time, up to 28 days after randomization. All treated patients received aspirin. The results indicate that there were 1645 deaths in the placebo group (8.1%) and 1726 deaths in the clopidogrel group (7.5%). The text also mentions a proportional risk reduction of 5=0.03 before discharge.*

The text describes the results of a study comparing the effect of placebo versus clopidogrel in patients receiving aspirin. The study found that a higher percentage of patients in the placebo group experienced an event (10.1%) compared to the clopidogrel group (9.2%), resulting in a 9% proportional risk reduction. All patients in the study received aspirin.*

This is a table Figure 6 from the COMMIT Study that shows the effects of adding Clopidogrel to Aspirin, presented as an Odds Ratio (99% CT), on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups. The subgroups are divided by gender, age, hours since onset, SBP (blood pressure), heart rate and whether a fibrinolytic agent was given. The table shows the proportion of patients in each subgroup who received Clopidogrel vs. placebo, and the percentage of patients in each subgroup for whom Clopidogrel was more effective than placebo or the favouritism was in place of placebo for each category. The Overall row presents the results for the entire sample.*

The text is describing the cumulative event rate for fatal or non-fatal vascular events over a period of months of follow-up for a medication called Clopidogrel bisulfate. The data is presented in a table format with percentages for each month.*

This text appears to be a table with information related to patients with qualifying conditions such as stroke, MI (Myocardial Infarction), and PAD (Peripheral Artery Disease). The table includes data on the number of patients who were given Clopidogrel and Aspirin, with percentages and hazard ratios. The last row indicates which medication (Clopidogrel or Aspirin) is favored based on the hazard ratio. Without additional context, it is difficult to interpret the results of this table.*